Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 846-827-8 | CAS number: 1521274-68-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Based on GLP-conform in vitro skin sensitisation Turnkey Testing, the following results were achieved:
- DPRA, OECD 442C (peptide reactivity): negative
- LuSens, OECD 442D (keratinocyte activation): negative
- h-CLAT, OECD 442E (dendritic cell activation): positive
Conclusively, the test substance is predicted not to be a skin
sensitizer.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in chemico
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- March 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442C (In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA))
- Version / remarks:
- 04 February 2015
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Landesamt für Umwelt, Wasserwirtschaft und Gewerbeaufsicht; Kaiser-Friedrich-Straße 7, 55116 Mainz
- Type of study:
- direct peptide reactivity assay (DPRA)
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- batch No.of test material: L2018-006
- Expiration date of the batch: 01 Mar 2020
- Purity: 98.5% (tolerance +/- 1.0 %)
- Physical state / color: solid / white
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: ambient
- Stability under test conditions: Because the test-substance preparation was incubated with the peptide shortly after preparation, no analysis of the test substance in the vehicle was performed.
- Solubility and stability of the test substance in the solvent/vehicle: The stability under storage conditions over the study period was guaranteed.
TEST SUBSTANCE SOLUBILITY
- After stirring and ultrasonication the test substance was soluble (colloid solution) in the vehicle.
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- The test substance was prepared as a 100 mM preparation in acetonitrile considering a molecular weight of 123.16 g/mol and a purity/contents of 98.5%.
OTHER SPECIFICS:
- Identity: confirmed
- Homogeneity: given
- Molecular weight: 123.16 g/mol
- Log KOW: 0.06 (calculated)
- Proposed reaction mechanism for protein binding by OECD toolbox (non-GLP system): The OECD toolbox did not indicate an alert for protein binding for the substance. - Details on the study design:
- Skin sensitisation (In chemico test system) - Details on study design:
- EXPERIMENTAL PROCEDURE
The test substance was dissolved in a suitable vehicle. Three samples of the test substance were incubated with each peptide. Additionally, triplicates of the concurrent vehicle control (=NC) were incubated with the peptides. The remaining non-depleted peptide concentration was determined thereafter by HPLC with gradient elution and UV-detection at 220 nm. In addition, calibration samples of known peptide concentration, prepared from the respective peptide stock solution used for test-substance incubation, were measured in parallel with the same analytical method.
- TEST SUBSTANCE SOLUBILITY
Prior to the assay the solubility of the test substance at a concentration of 100 mM was tested. A suitable non-reactive, water-miscible solvent which dissolves the test substance completely (no visible precipitation or cloudyness of the test-susbtance preparation) should be used. The preferred solvent was acetonitrile. When not soluble in acetonitrile solutions in water, isopropanol, acetone, propanol, methanol or mixtures of these solvents were tried.
- SYNTHETIC PEPTIDES:
-Cysteine- (C-) containing peptide: Ac-RFAACAA-COOH (MW=751.9 g/mol)
-Lysine- (K-) containing peptide: Ac-RFAAKAA-COOH (MW=776.2 g/mol)
The peptides are custom material (Supplier: GenScript, Piscataway, NJ, USA) containing phenylalanine to aid in detection and either cysteine or lysine as the reactive center.
- CONTROLS
-Negative control (NC): vehicle control = acetonitrile
-Positive control (PC): Ethylene glycol dimethacrylate (EGDMA; CAS-no. 97-90-5), prepared as a 50 mM solution in acetonitrile
-Co-elution control (SK): Sample prepared of the respective peptide buffer and the test substance but without peptide.
- SELECTION OF CONCENTRATIONS
The test substance was prepared at a 100 mM concentration considering a purity/contents of 98.5% and molecular weight of 123.16 g/mol. The C-containing peptide was incubated with the test substance in a ratio of 1:10 (0.5 mM peptide, 5 mM test substance) and the K-containing peptide in a ratio of 1:50 (0.5 mM peptide, 25 mM test substance).
- PREPARATION OF PEPTIDE STOCK SOLUTIONS
Peptide stock solutions in a concentration of 0.667 mM were prepared in pH 7.5 phosphate buffer (C-containing peptide) or pH 10.2 ammonium acetate buffer (K-containing peptide). The peptide stock solution was used for preparing the calibration samples and the test substance and control samples.
- PREPARATION OF CALIBRATION SAMPLES (see table 1)
The calibration samples were prepared from the peptide stock solutions in 20% acetonitrile in the respective buffer (= dilution buffer). The analysis of the calibration samples was started before analysis of the test-substance samples.
- TEST SUBSTANCE PREPARATION
The test substance was prepared as a 100 mM preparation in acetonitrile considering a molecular weight of 123.16 g/mol and a purity/contents of 98.5%. After stirring and ultrasonication the test substance was soluble (colloid solution) in the vehicle.
Vehicle: Acetonitrile
Reason for the vehicle: The test substance was soluble (colloid solution) in acetonitrile.
- PREPARATION OF THE TEST-SUBSTANCE SAMPLES
The samples were prepared in triplicates for each peptide according to the pipetting scheme given in table 2. The samples were prepared in suitable tubes, capped tightly and incubated at 25°C ± 2.5°C in the dark for 24 ± 2 hours. Visual inspection for solubility was performed directly after sample preparation and prior to HPLC analysis. Unsolved samples were centrifuged and/or filtrated prior to injection into the HPLC in order to remove any unsolved particles. The HLPC analysis of the batch of samples started about 24 hours after sample preparation and the analysis time itself did not exceed 30 hours.
- PREPARATION OF THE VEHICLE CONTROLS
Several vehicle controls were prepared in triplicates in the same way as the test-substance samples described above but with the vehicle (deionized water) instead of the test substance:
One set (set A) was analyzed together with the calibration samples without incubation and serves as a performance control. Another three sets (two sets B and set C) were prepared and incubated with the samples. Sets B were placed at the very start and ending of the sample list and serve as stability control of the peptide over the analysis time. Set C was analyzed with the samples and serves for calculation of the peptide depletion of any chemical formulated in the vehicle.
- PREPARATION OF THE CO-ELUTION CONTROL
One sample per peptide was prepared in the same way as the test-substance samples described above but without the peptides. Instead the respective peptide buffer was used. The samples were analyzed together with the calibration samples. Samples which were visually turbid or display precipitates were centrifuged and/or filtrated prior to injection into the HPLC in order to remove any unsolved particles.
- MEASUREMENT OF PEPTIDE CONCENTRATIONS
The analyses of the samples were performed via HPLC under the conditions given in table 3.
- DATA EVALUATION
The integrated peak areas were transferred electronically into EXCEL data spreadsheets to carry out the necessary calculations. Some test substances or reaction products may co-eluate with the peptides. In these cases where proper integration and calculation of peptide depletion was not possible, the result for the respective peptide is reported as interference. For evaluation of peptide depletions peak areas at 220 nm are used. When samples were additionally analyzed by measuring UV absorbance at 258 nm, the area ratio 220 nm/ 258 nm may be calculated and serve as a measure of peak purity. The ratio of a pure peptide peak should be consistent over all samples (100% ± 10% of the mean of the vehicle controls). However, due to small peak areas calculation of the area ratio may not be possible for all samples (evaluation criteria see tables 4 and 5).
- ACCEPTANCE CRITERIA
- The standard calibration curve should have an r² > 0.99.
- The negative control (vehicle control) samples of sets A and C should be 0.50 mM +/- 0.05 mM.
- The CV of the nine vehicle controls B and C should be < 15%.
- Since the mean peptide depletion for each peptide is determined from the mean of three single samples, the variability between these samples should be acceptably low (SD < 14.9% for % cysteine depletion and < 11.6% for % lysine depletion).
- In addition the positive control should cause depletion of both peptides comparable to historic data. - Positive control results:
- Positive control (EGDMA):
Mean depletion (Cysteine-Peptide): 52.76% (+/- 2.72)
Mean depletion (Lysine-Peptide): 9.08% (+/- 0.94)
Mean of both depletions: 30.92% - Parameter:
- other: Mean depletion (Cysteine-Peptide) [%]
- Value:
- 1.32
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Parameter:
- other: Mean depletion (Lysine-Peptide) [%]
- Value:
- -0.21
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Parameter:
- other: Mean of both depletions [%]
- Value:
- 0.66
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Other effects / acceptance of results:
- ACCEPTANCE OF RESULTS:
- Acceptance criteria met for negative control: yes
- Acceptance criteria met for positive control: yes
- Acceptance criteria met for variability between replicate measurements: yes - Interpretation of results:
- other: Non peptide binding/peptide binding
- Conclusions:
- No predictions can be made for skin sensitisation according to GHS criteria based on the results of this in vitro study alone.
In the present study, the test substance shows minimal or no peptide binding and therefore minimal or no chemical reactivity under the test conditions chosen. - Executive summary:
The objective was to assess the skin sensitizing potential of the test substance. A combination of the following three in vitro methods, addressing key events of the adverse outcome pathway (AOP) for skin sensitization (OECD, 2012) as defined by the OECD, were part of this in vitro Skin Sensitization Turnkey Testing Strategy:
• protein reactivity (DPRA),
• activation of keratinocytes (LuSens), and
• activation of dendritic cells (h-CLAT).
DPRA:
The reactivity of the test substance towards synthetic cysteine (C)- or lysine (K)-containing peptides was evaluated in the Direct Peptide Reactivity Assay (DPRA). For this purpose, the test substance was incubated with synthetic peptides for ca. 24 hours at ca. 25°C and the remaining non-depleted peptide concentrations were determined by high performance liquid chromatography (HPLC) with gradient elution and UV-detection at 220 nm. The test substance was dissolved at 100 mM in acetonitrile. Three samples of the test substance were incubated with each peptide in ratios of 1:10 (for C-containing peptide) or 1:50
(for K-containing peptide). Additionally, triplicates of the concurrent vehicle control (= VC) were incubated with the peptides. Further, in order to detect possible interference of the test substance with the peptides, a coelution control was performed and the samples were analyzed by measuring UV absorbance at 258 nm in order to calculate the area ratio 220 nm / 258 nm. The following results were obtained in the DPRA:
The test substance was dissolved in acetonitrile at a concentration of 100 mM (colloid solution). The samples of the test substance with the peptides were solutions at the time of preparation. Visual observation after the 24-hour incubation time did not reveal precipitates in any samples of the test substance with the peptides. No co-elution of test substance and peptides was present. The mean C-peptide depletion, caused by the test substance was determined to be 1.32%. The mean K-peptide depletion, caused by the test substance was determined to be -0.21%. Negative depletions were considered to be “zero” for calculation of the mean peptide depletion, which was thus calculated to be 0.66%. Based on the observed results and applying the cysteine 1:10 / lysine 1:50 prediction model cited in chapter 3.10 it was concluded that the test substance shows minimal or no chemical reactivity in the DPRA under the test conditions chosen.
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- March - May 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442D (In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method)
- Version / remarks:
- 25 Jun 2018
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Landesamt für Umwelt, Wasserwirtschaft und Gewerbeaufsicht; Kaiser-Friedrich-Straße 7, 55116 Mainz
- Type of study:
- activation of keratinocytes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- batch No.of test material: L2018-006
- Expiration date of the batch: 01 Mar 2020
- Purity: 98.5% (tolerance +/- 1.0 %)
- Physical state / color: solid / white
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: ambient
- Stability under test conditions: Because the test-substance preparation was applied shortly after preparation, no analysis of the test substance in the vehicle was performed.
- Solubility and stability of the test substance in the solvent/vehicle: The stability under storage conditions over the study period was guaranteed.
TEST SUBSTANCE SOLUBILITY
- After stirring and ultrasonication the test substance was soluble in 4% DMSO in culture medium 3. Visual inspection of each dilution step was performed.
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- The test substance was weighed and topped up with the chosen vehicle (4% DMSO in culture medium 3) to achieve the required 4x concentration of the highest concentration (stock solution). Further concentrations were prepared as 4x concentrations by serial 1:1.2 dilution.
OTHER SPECIFICS:
- Identity: confirmed
- Homogeneity: given
- Molecular weight: 123.16 g/mol
- Log KOW: 0.06 (calculated) - Details on the study design:
- Skin sensitisation (In vitro test system) - Details on study design:
- SELECTION OF CONCENTRATIONS
In order to determine the concentrations suitable for the main experiment a pre-test (experimental conduct in accordance with GLP but without a GLP status) was performed. Cells were exposed to 9 concentrations of the test-substance preparation as provided by the sponsor (0.5 μM up to 2030 μM corresponding to final test-substance concentrations of 0.5 μM up to 2000 μM taking a purity/contents of 98.5% into account) and cytotoxicity was determined by MTT assay. The CV75 value (= estimated concentration that affords 75% cell viability) of the test substance was determined by linear regression from the concentration response curve to be 1044 μM (test substance as provided by the sponsor).
The highest tested concentration in the 1st main experiment was 1.23-fold of the CV75 value. The additional concentrations were obtained by a 1:1.2 serial dilution series of the maximum concentration (concentration selection for the 1st experiment [µM]: 503, 604, 725, 870, 1044, 1253, 1503, 1804). As no rel. viability below 70% was observed in the 1st experiment, higher concentrations were tested in further experiments (concentration selection for the 2nd and 3rd experiment [µM]: 567, 680, 816, 979, 1175, 1410, 1692, 2030).
- CELL LINE LuSens (Human transgenic keratinocyte cell line derived from HaCaT cells, prepared in collaboration with Christoph J. Wruck, RWTH Aachen, Germany)
- CONTROLS
- Negative control (NC): DL-Lactic acid (LA, CAS no.: 50-21-5), 5000 μM (= 450 μg/mL) in 1% DMSO in culture medium 3
- Positive control (PC): Ethylene glycol dimethacrylate (EGDMA, CAS no.: 97-90-5), 90.8 μM (= 18 μg/mL) in 1% DMSO in culture medium 3
- Vehicle control (VC): 1% DMSO in culture medium 3
- Blank control: culture medium 3 without cells
- Basal control: culture medium 3 with cells
- TEST-SUBSTANCE PREPARATIONS
The test substance was weighed and topped up with the chosen vehicle (4% DMSO in culture medium 3) to achieve the required 4x concentration of the highest concentration (stock solution). Further concentrations were prepared as 4x concentrations by serial 1:1.2 dilution according to the planned concentrations (master plate). The test-substance preparations were prepared by stirring and ultra-sonication.
- PREPARATION OF THE CELLS
LuSens cells from the working cell bank were thawed and cultured using culture medium 1, under standard culture conditions (37°C, ca. 5% CO2, ≥ 90% relative humidity) for at least passage ≥5 but not longer than 15 passages prior to testing. Before substance incubation, cells were seeded in 96-well microtiter plates (120 μL of 0.83 x 105 cells/mL cell suspension), using culture medium 2 for incubation for ca. 24 hours. Three independent, valid experiments were performed. In each experiment, three replicates of each test-substance concentration were tested.
- TEST-SUBSTANCE APPLICATION FOR MTT AND LUCIFERASE ASSAY
After cell adaption for ca. 24 hours culture medium 2 was aspirated and replaced with 150 μL culture medium 3. The test substance was prepared as described in section 3.5.2. Each preparation of the dilution plate was then applied in a ratio of 1:4 (50 μL) to the cells (final DMSO concentration in the test medium = 1%). After test-substance application the plates were sealed with plate sealers in order to prevent evaporation of the test substance. The plates were placed into the incubator under standard
culture conditions for the exposure period of 48 ± 1 hours. For the luciferase assay a white plate (luminescence compatible plate) was used. In addition, a clear plate was treated in parallel for the determination of cell viability.
- VISUAL INSPECTIONS
Each test-substance concentration was visually inspected directly after application and after the exposure period of 48 ± 1 hours in order to detect test-substance precipitates.
- LUCIFERASE ASSAY
After visual inspection of the cells, the supernatant was aspirated from the white assay plate and discarded. The cells were washed twice with 300 μL PBS (with Ca2+/Mg2+). Subsequently 200 μL of One-Glo-preparation (= 100 μL One-Glo- Mix and 100 μL PBS (without Ca2+/Mg2+)) per well was added and cells were shaken on a plate shaker for ca. 10 min at room temperature in darkness. After the incubation the luminescence was measured in the luminometer.
- CELL VIABILITY ASSAY MTT
Cell culture medium was aspirated from all wells. The cells were washed twice with 300 μL PBS (with Ca2+/Mg2+). Thereafter 200 μL of a 0.5 mg/mL thiazolyl blue tetrazolium bromide (MTT) solution (prepared 1:10 from a 5 mg/mL (MTT) stock solution in PBS (without Ca2+/Mg2+) and culture medium 3) was added to each well of the 96-well microtiter plate and incubated for at least further 2 hours in the incubator. For analysis, medium was aspirated and cells were lysed by adding 100 μL of lysis solution (99.6 mL DMSO; 10 g sodium dodecyl sulfate, SDS; and 0.4 mL glacial acetic acid). Absorbance was measured at 570 nm with reference wavelength 690 nm using a spectral-photometer.
- STATISTICAL ANALYSES
For the statistical evaluation of luciferase fold induction the EXCEL-function T.TEST is used (see table 1).
- ACCEPTANCE CRITERIA
- A tested concentration is not further evaluated when relative viability is less than 70%.
- The cell viability of VC cells must yield at least 85%.
- The mean of the positive control EGDMA should achieve ≥ 2.50 fold-induction and the mean of the LA < 1.50 and the mean of the viability must be ≥70%.
- The CV [%] of the luminescence in the vehicle control wells for each plate should be below 20%.
- The mean of the basal expression of the cells must be <1.50 as compared to the solvent control.
- In addition, positive, negative and vehicle control data should lie within the range of the historic data.
- EVALUATION OF THE RESULTS
A test substance is concluded to exhibit a keratinocyte activating potential when the luciferase activity exceeds a 1.50 fold-induction of statistical significance with respect to the vehicle control at concentrations that do not reduce viability below 70% in at least two consecutive concentrations of two independent experiments. A test substance is considered to be negative when the criteria mentioned above are not met up to the maximum concentration (= 2000 μM if molecular weight is applicable or 2000 μg/mL if molecular weight is not applicable) or up to the cytotoxicity limit (at least one concentration displaying viability below 70%). To be relevant for evaluation, the cell viability must be more than 70% in at least three tested concentrations of an experiment. - Positive control results:
- Positive control: EGDMA 90.8 µM
mean (fold induction): 5.42 (1st experiment) / 3.89 (2nd experiment) / 3.60 (3rd experiment) - Run / experiment:
- other: 1-3
- Parameter:
- other: EC1.50
- Remarks:
- Calculation of an EC1.50 was not applicable as luciferase fold induction did not exceed 1.50.
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Other effects / acceptance of results:
- - RESULTS OF PRELIMINARY CYTOTOXICITY ASSESSMENT (see table 2):
The final test substance concentrations were calculated considering a purity/contents of 98.5%. The CV75 value (= estimated concentration that affords 75% cell viability) was determined by linear regression from the concentration-response curve to be 1044 μM (test substance as provided by the sponsor).
- ACCEPTANCE OF RESULTS:
- Acceptance criteria met for negative control: yes
- Acceptance criteria met for positive control: yes
- Acceptance criteria met for variability between replicate measurements: yes - Interpretation of results:
- other: no keratinocyte activating potential
- Conclusions:
- No predictions can be made for skin sensitisation according to GHS criteria based on the results of this in vitro study alone.
In the present study, the test substance does not have a keratinocyte activating potential. - Executive summary:
The objective was to assess the skin sensitizing potential of the test substance. A combination of the following three in vitro methods, addressing key events of the adverse outcome pathway (AOP) for skin sensitization (OECD, 2012) as defined by the OECD, were part of this in vitro Skin Sensitization Turnkey Testing Strategy:
• protein reactivity (DPRA),
• activation of keratinocytes (LuSens), and
• activation of dendritic cells (h-CLAT).
LuSens:
The keratinocyte activating potential of the test substance was evaluated in the LuSens assay. For this purpose, the test substance was incubated with a luciferase reporter cell line (LuSens cells) for ca. 48 hours at 37°C and antioxidant response element (ARE) dependent luciferase activity was measured in a luminometer. In order to determine the concentrations suitable for the main experiment a pre-test (non-GLP)
was performed. Cells were exposed to several concentrations of the test substance and cytotoxicity was determined by MTT assay. The CV75 value (= estimated concentration that affords 75% cell viability) was determined by linear regression from the concentration-response curve to be 1044 μM (corresponding to test substance as provided by the sponsor). In the main test luciferase activity was measured after 48-hour exposure. In parallel a MTT assay was performed to assess cytotoxicity of the test substance. A total of 3 valid experiments were performed. The following results were observed: The test substance was soluble in 4% DMSO in culture medium 3 (4 x stock preparations) and in 1% DMSO in culture medium 3 (final concentrations). No precipitates were noticed in any concentration after 48 hours.
Calculation of an EC1.50 (the concentration resulting in a 1.50-fold luciferase induction) was not applicable as luciferase fold induction did not exceed 1.50. In summary, after 48 hours of exposure to the test substance luciferase activity in LuSens cells was not induced in at least two consecutive concentrations with statistical significance affording at least 70% viability in at least two independent experiments. From this it has to be concluded that the test substance does not have a keratinocyte activating potential.
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- March - April 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- other: OECD442E "In vitro skin sensitisation assays addressing the key event on activation of dendritic cells on the adverse outcome pathway for skin sensitisation"
- Version / remarks:
- 25 Jun 2018
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Landesamt für Umwelt, Wasserwirtschaft und Gewerbeaufsicht; Kaiser-Friedrich-Straße 7, 55116 Mainz
- Type of study:
- activation of dendritic cells
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- batch No.of test material: L2018-006
- Expiration date of the batch: 01 Mar 2020
- Purity: 98.5% (tolerance +/- 1.0 %)
- Physical state / color: solid / white
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: ambient
- Stability under test conditions: The h-CLAT was performed in an aqueous test system. Due to the use of culture medium as vehicle the verification of the stability of the test substance in the vehicle is not required.
- Solubility and stability of the test substance in the solvent/vehicle: The stability under storage conditions over the study period was guaranteed.
TEST SUBSTANCE SOLUBILITY
- After stirring the test substance was soluble in culture medium. Visual inspection of each dilution step was performed.
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- The test substance was weighed and topped up with the chosen vehicle (culture medium) to achieve the required 2x concentration of the highest concentration (stock solution). Further concentrations were prepared as 2x concentrations by serial 1:1.2 dilution.
OTHER SPECIFICS:
- Identity: confirmed
- Homogeneity: given
- Molecular weight: 123.16 g/mol
- Log KOW: 0.06 (calculated) - Details on the study design:
- Skin sensitisation (In vitro test system) - Details on study design:
- PREPARATION OF THE CELLS
THP-1 cells from the working cell bank were thawed and cultured in suspension using complete RPMI 1640 medium supplemented with 10% fetal bovine serum (heat inactivated), 100 U/mL penicillin, 100 μg/mL streptomycin and 0.05 mM 2-mercaptoethanol under standard culture conditions (37°C, ca. 5% CO2, ≥ 90% relative humidity) until for 5 passages but not longer than passage 30 prior to testing.
Prior to use of the cells for a study, a reactivity check was performed with each new-thawed cells, as proposed in the OECD test guideline, using Nickel(II)sulfate hexahydrate, lactic acid and 1- chloro-2,4-dinitrobenzene in order to demonstrate qualification of the cells for the assay.
For substance incubation, cells were seeded in 24-well plates (500 μL of 2.0 x 106 cells/mL cell suspensions). Three independent, valid experiments were performed. In each experiment, duplicates of each test-substance concentration were tested; however, in the second experiment one sample could be evaluated only, due to a technical error.
- SELECTION OF CONCENTRATIONS
In order to determine the concentrations suitable for the main experiment a pre-test (experimental conduct in accordance with GLP but without a GLP status) was performed. Cells were exposed to 11 concentrations of the test-substance preparation as provided by the sponsor (4 μg/mL up to 5076 μg/mL corresponding to final test substance ingredient concentrations of 4 μg/mL up to 5000 μg/mL taking the purity of 98.5% into account) and cytotoxicity was determined thereafter by propidium iodide (PI) intercalation into the DNA. The CV75 value (= estimated concentration that affords 75% cell viability) of the test substance was determined by linear regression from the concentration response curve to be 23251 μg/mL (test substance as provided by the sponsor). The highest tested concentration in the 1st main experiment was 1.2-fold of the CV75 value. The additional concentrations were obtained by a 1:1.2 serial dilution series of the maximum concentration (concentration selection for the main experiments [µg/mL]: 779, 935, 1122, 1346, 1615, 1938, 2326, 2791).
- CELL LINE: THP-1 cells (The human monocytic leukemia cell line was obtained from “American Type Culture Collection, Manassas, USA” (ATCC, TIB-202).
- TEST SUBSTANCE PREPARATION
The test substance was weighed and topped up with the chosen vehicle (culture medium) to achieve the required 2x concentration of the highest concentration (stock solution). Further concentrations were prepared as 2x concentrations by serial 1:1.2 dilution according to the planned concentrations in culture medium. The test-substance preparations were prepared by stirring.
Reason for the vehicle: The test substance was soluble in culture medium.
Form of application: Visual inspection of each dilution step was performed.
- TEST-SUBSTANCE APPLICATION
Treatment was performed by adding 500 μL of test-substance preparation to the cells, thus diluting the 2x concentrated test-substance preparations to their final concentration and the cells to 1.0 x 106 cells/mL. After test-substance application the plates were sealed with plate sealers in order to prevent evaporation of the test substance. The plates were placed into the incubator under standard culture conditions for the exposure period of 24 ± 0.5 hours.
- VISUAL INSPECTIONS
Each test-substance concentration was visually inspected directly after application and after the exposure period of 24 ± 0.5 hours in order to detect test-substance precipitates.
- CELL STAINING AND FLOW CYTOMETRIC ANALYSIS
After visual inspection the cells were transferred into safe-lock tubes, collected by centrifugation and washed twice with 1 mL buffer. Cells were incubated with 600 μL of 0.01% Globulins Chon fraction II,III at 4°C for 15 min to block FC receptors (FcR). After FcR blocking, cells of each treatment condition were divided into 3 aliquots (approximately 0.3 x 106 cells/180 μL/group) in 96-well microtiter plates. Cells were centrifuged, supernatant was discarded and 50 μL working antibody solution was added to each pellet. Working solutions of the antibodies were prepared (see table 1). Cell staining was performed at 4°C for ca. 30 min in the dark. After staining the cells were washed twice with 200 μL buffer and finally re-suspended in 200 μL buffer. Before analysis in flow cytometer the cells were stained with 5 μL of PI (50 μg/mL diluted in buffer) to yield a final concentration of 1.22 μg/mL PI.
- ACCEPTANCE CRITERIA
- A tested concentration is not to be further evaluated when relative viability is less than 50%.
- Cell viability of vehicle control cells must yield at least 90%.
- In the positive control (DNCB), RFI values of both CD86 and CD54 should be over the positive criteria (CD86≥ 150% and CD54 ≥ 200%) and cell viability should be ≥ 50%.
- In the negative control (LA), RFI values of both CD86 and CD54 should not exceed the positive criteria (RFI CD86< 150% and RFI CD54 < 200%) and cell viability should be ≥ 50%.
- For all vehicle controls, the MFI ratio of both CD86 and CD54 to isotype controls should be ≥105%.
-The reactivity check of new thawed cells should produce the following result:
- Positive response in CD86 and CD54 for NiSO4 and DNCB
- Negative response in CD86 and CD54 for LA.
-In addition, positive, negative and vehicle control data should lie within the range of the historic data.
- EVALUATION OF THE RESULTS
A test substance is predicted to activate monocytic THP-1 cells when CD86 expression is increased ≥ 150% and/or CD54 expression increased ≥ 200% at any concentration in relation to vehicle control that do not reduce viability below 50% and reproduced in the same cell surface marker in at least two independent experiments. A test substance is considered to be negative when the criteria mentioned above are not met up to the maximum concentration (= 5000 μg/mL for the vehicle culture medium or 1000 μg/mL for 0.2% DMSO in culture medium) or up to the cytotoxicity limit (viability less than 90% at the highest concentration tested). To be relevant for evaluation, the cell viability must be more than 50% in at least four tested concentrations of an experiment.
- CONTROLS
Negative control (NC): Lactic acid (LA, CAS no.: 50-21-5), 1000 μg/mL in culture medium
Positive control (PC): 1-chloro-2,4-dinitrobenzene (DNCB, CAS no.: 97-00-7), 4.0 μg/mL in 0.2% DMSO in culture medium
Vehicle control (VC): culture medium
Isotype control: In order to help distinguish non-specific (“background”) staining from specific antibody staining each test-substance concentration and control is additionally incubated with mouse IgG1. - Positive control results:
- Positive control: DNCB 4 µg/mL:
- RFI CD86 mean [%]: 290 (1st experiment) / 236 (2nd experiment) / 251 (3rd experiment)
- RFI CD54 mean [%]: 657 (1st experiment) / 843 (2nd experiment) / 548 (3rd experiment)
- Rel. Viability [%]: 59 (1st experiment) / 83 (2nd experiment) / 68 (3rd experiment) - Run / experiment:
- other: 3
- Parameter:
- other: EC150% for CD86 [µg/mL]
- Value:
- 1 055
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- positive indication of skin sensitisation
- Run / experiment:
- other: 2
- Parameter:
- other: EC200% for CD54[µg/mL]
- Value:
- 1 024
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- positive indication of skin sensitisation
- Other effects / acceptance of results:
- The CV75 value (= estimated concentration that affords 75% cell viability) was determined by linear regression from the concentration-response curve to be 2325 μg/mL (test substance as provided by the sponsor).
ACCEPTANCE OF RESULTS:
- Acceptance criteria met for negative control: Yes
- Acceptance criteria met for positive control: Yes
- Acceptance criteria met for variability between replicate measurements: Yes - Interpretation of results:
- other: positive indication of skin sensitisation
- Conclusions:
- No prediction can be made for skin sensitisation according to GHS criteria based on the results of this in vitro study alone.
According to the results of the present study, the test substance induces dendritic cell activation, which is indicative of skin sensitisation. - Executive summary:
The objective was to assess the skin sensitizing potential of the test substance. A combination of the following three in vitro methods, addressing key events of the adverse outcome pathway (AOP) for skin sensitization (OECD, 2012) as defined by the OECD, were part of this in vitro Skin Sensitization Turnkey Testing Strategy:
• protein reactivity (DPRA),
• activation of keratinocytes (LuSens), and
• activation of dendritic cells (h-CLAT).
h-CLAT:
The potential of the test substance to induce the cell membrane markers CD86 and CD54 expression was evaluated in the Human Cell Line Activation Test (h-CLAT). For this purpose, the test substance was incubated with human monocytic leukemia cell line THP-1 for ca. 24 hours at 37°C and membrane marker expression (CD86 / CD54) was measured by flow cytometry.
In order to determine the concentrations suitable for the main experiment a pre-test (non-GLP) was performed. Cells were exposed to several concentrations of the test substance and cytotoxicity was determined thereafter by propidium iodide (PI) intercalation into the DNA. The CV75 value (= estimated concentration that affords 75% cell viability) was determined by linear regression from the concentration-response curve to be 2325 μg/mL (corresponding to test substance as provided by the sponsor).
In the main test after 24-hour exposure THP-1 cells were stained with FITC labeled anti-human-CD86/ anti-human-CD54 antibody and propidium iodide and the fluorescence intensity was analyzed using flow cytometry. A total of 3 valid experiments were performed although the result of the 2nd experiment confirmed the result of the 1st experiment, as one sample instead of two samples was available in the 2nd experiment, only, due to a technical error. The following results were observed:
The test substance was soluble in culture medium (2 x stock preparations and final concentrations). No precipitates were noticed in any concentration after 24 hours.
The EC150% (the concentration resulting in a RFI of 150%) for CD86 was calculated to be 1055 μg/mL (experiment 3). The EC200% (the concentration resulting in a RFI of 200%) for CD54 was calculated to be 1024 μg/mL (experiment 2).
Calculation of EC150% for CD86 and EC200% for CD54 was not applicable for the other experiments.
In summary, after 24 hours of exposure to the test substance, CD86 and CD54 expression was induced in THP-1 cells affording at least 50% viability in at least two independent experiments. From this it has to be concluded that the test substance induces dendritic cell activation.
Referenceopen allclose all
Table 6: Mean peptide depletions of Cysteine, Lysine and both peptides.
|
Cysteine-Peptide
mean depletion [%] SD [%] |
Lysine-Peptide
mean depletion [%] SD [%] |
mean of both depletions [%] |
||
test substance |
1.32 |
0.79 |
-0.21 |
0.37 |
0.66 |
PC:EGDMA in ACN |
52.76 |
2.72 |
9.08 |
0.94 |
30.92 |
Table 7: Peptide depletion of NC, PC and the test substance for cysteine-peptide.
Reaction with cysteine- peptide |
peptide depletion [%] |
|||
sample 1 |
sample 2 |
sample 3 |
mean SD |
|
NC: ACN |
-0.13 |
0.16 |
-0.03 |
0.00 0.15 |
test substance |
0.42 |
1.66 |
1.89 |
1.32 0.79 |
PC:EGDMA in ACN |
50.01 |
52.83 |
55.45 |
52.76 2.72 |
Table 8: Peptide depletion of NC, PC and the test substance for lysine-peptide.
Reaction with lysine- peptide |
peptide depletion [%] |
|||
sample 1 |
sample 2 |
sample 3 |
mean SD |
|
NC: ACN |
-0.05 |
-0.09 |
0.14 |
0.00 0.12 |
test substance |
-0.28 |
0.19 |
-0.53 |
-0.21 0.37 |
PC:EGDMA in ACN |
9.67 |
9.58 |
8.00 |
9.08 0.94 |
Table 9: Historic control data of negative control / vehicle control (not including present study). Acetonitrile (Historic period: Jan 2017 - Feb 2019)
|
C-peptide concentration [mM] |
K-peptide concentration [mM] |
Min |
0.432 |
0.457 |
Max |
0.564 |
0.548 |
Mean |
0.492 |
0.504 |
SD |
0.030 |
0.015 |
n |
34 |
33 |
Table 10: Historic control data of positive control (not including present study). EGDMA, 50 mM in acetonitrile (Historic period: Jan 2017 - Feb 2019)
|
Table 2: Results of preliminary cytotoxicity assessment.
Concentration (final test substance) [µM] |
Concentration (test substance) [µM] |
mean OD570-690 of 3 replicates |
mean rel Viability [%] |
VC |
VC |
0.306 |
100 |
0.5 |
0.5 |
0.298 |
98 |
1 |
1 |
0.296 |
97 |
5 |
5 |
0.292 |
95 |
10 |
10 |
0.281 |
92 |
50 |
51 |
0.280 |
92 |
100 |
102 |
0.245 |
80 |
500 |
508 |
0.239 |
78 |
1000 |
1015 |
0.231 |
75 |
2000 |
2030 |
0.182 |
60 |
Table 3: Summary of LuSens Main Experiments
A total of 3 valid experiments were performed. However, in the 1st experiment the concentrations selected were too low (no viability < 70% or keratinocyte activating effect were observed) and the experiment is not useful for evaluation. Concentrations with fold inductions above 1.50 with rel. viability ≥70% and with statistical significance are indicated in bold and in grey when < 70% viability.
Concentration (test substance) [µM] |
1stexperiment fold induction rel. viability [%] |
t-test |
Concentration (test substance) [µM] |
fold induction |
2ndexperiment rel. viability [%] |
t-test |
|||||
mean |
mean |
p-value |
markers |
mean |
mean |
p-value |
markers |
||||
503 |
1.02 |
84 |
0.125 |
n.s. |
567 |
0.88 |
73 |
0.033 |
* |
||
604 |
1.14 |
85 |
0.072 |
n.s. |
680 |
0.93 |
75 |
0.136 |
n.s. |
||
725 |
1.08 |
80 |
0.151 |
n.s. |
816 |
0.86 |
72 |
0.066 |
n.s. |
||
870 |
0.91 |
80 |
0.113 |
n.s. |
979 |
0.83 |
70 |
0.000 |
** |
||
1044 |
0.83 |
77 |
0.000 |
** |
1175 |
0.96 |
71 |
0.319 |
n.s. |
||
1253 |
0.75 |
75 |
0.000 |
** |
1410 |
0.88 |
66 |
0.072 |
n.s. |
||
1503 |
0.72 |
73 |
0.001 |
** |
1692 |
0.99 |
68 |
0.463 |
n.s. |
||
1804 |
0.60 |
70 |
0.005 |
** |
2030 |
1.05 |
63 |
0.251 |
n.s. |
||
VC |
1.00 |
100 |
- |
- |
VC |
1.00 |
100 |
- |
- |
||
EGDMA 90.8 µM |
5.42 |
100 |
0.000 |
** |
EGDMA 90.8 µM |
3.89 |
75 |
0.000 |
** |
||
LA 5000 µM |
0.96 |
100 |
0.143 |
n.s. |
LA 5000 µM |
0.86 |
86 |
0.016 |
* |
||
Concentration |
3rdexperiment fold induction rel. viability [%] t-test |
|
|||||||||
(test substance) |
|||||||||||
[µM] |
mean |
mean |
p-value |
markers |
|||||||
567 |
0.71 |
86 |
0.000 |
** |
|||||||
680 |
0.72 |
68 |
0.004 |
** |
|||||||
816 |
0.64 |
84 |
0.000 |
** |
|||||||
979 |
0.63 |
80 |
0.000 |
** |
|||||||
1175 |
0.66 |
79 |
0.002 |
** |
|||||||
1410 |
0.63 |
75 |
0.006 |
** |
|||||||
1692 |
0.58 |
68 |
0.005 |
** |
|||||||
2030 |
0.57 |
72 |
0.000 |
** |
|||||||
VC |
1.00 |
100 |
- |
- |
|||||||
EGDMA 90.8 µM |
3.60 |
91 |
0.000 |
** |
|||||||
LA 5000 µM |
0.93 |
99 |
0.083 |
n.s. |
Table 4: Historic control data. Data shown of test period Mar 2017 until May 2019 (not including present study).
Negative Control (5000 µM (= 450 µg/mL)) |
fold induction |
rel. viability [%] |
Min |
0.71 |
88 |
Max |
1.13 |
140 |
Mean |
0.93 |
102 |
SD |
0.09 |
8 |
n |
201 |
184 |
Positive Control EGDMA (90.8 µM (= 18 µg/mL)) |
fold induction |
rel. viability [%] |
Min |
2.83 |
70 |
Max |
8.64 |
122 |
Mean |
5.33 |
87 |
SD |
1.15 |
10 |
n |
201 |
184 |
Vehicle Control (1% DMSO) |
fold induction |
rel. viability [%] |
Min |
1.00 |
100 |
Max |
1.00 |
100 |
Mean |
1.00 |
100 |
SD |
0.00 |
0 |
n |
201 |
184 |
Basal expression |
fold induction |
rel. viability [%] |
Min |
0.61 |
121 |
Max |
1.32 |
179 |
Mean |
0.93 |
141 |
SD |
0.13 |
12 |
n |
201 |
184 |
Table 2: h-CLAT. Results of preliminary cytotoxicity assessment. The final test substance concentrations were calculated considering the purity/contents of 98.5%.
Concentration (final test substance) [µg/mL] |
Concentration (test substance) [µg/mL] |
%PI negative cells replicate 1 |
%PI negative cells replicate 2 |
mean viability of duplicates |
rel. viability mean [%] |
VC |
VC |
97 |
97 |
97 |
100 |
3.9 |
4 |
98 |
97 |
97 |
100 |
7.8 |
8 |
97 |
97 |
97 |
100 |
16 |
16 |
97 |
97 |
97 |
100 |
31 |
32 |
97 |
97 |
97 |
100 |
63 |
63 |
97 |
98 |
97 |
100 |
125 |
127 |
97 |
97 |
97 |
100 |
250 |
254 |
97 |
97 |
97 |
100 |
500 |
508 |
97 |
97 |
97 |
99 |
1000 |
1015 |
96 |
95 |
95 |
98 |
2500 |
2538 |
72 |
67 |
69 |
71 |
5000 |
5076 |
2 |
5 |
3 |
3 |
Table 3: Summary of h-CLAT main experiments: mean values of RFI CD86, RFI CD54 and relative viability.
3 valid experiments were performed. However, in the second experiment one sample instead of two samples is available for each concentration, only, due to a technical error. RFI above 150% (CD86) or 200% (CD54) with rel. viability ≥50% are indicated in bold.
1stexperiment |
2ndexperiment |
||||||
Concentration(testsubstance)[µg/mL] |
RFI CD86 |
RFI CD54 |
Viability rel. viability [%] |
Concentration(testsubstance)[µg/mL] |
RFI CD86 |
RFI CD54 |
Viability rel. viability [%] |
mean [%] |
mean [%] |
mean [%] |
mean [%] |
||||
779 |
156 |
221 |
97 |
779 |
147 |
145 |
99 |
935 |
160 |
276 |
93 |
935 |
148 |
180 |
97 |
1122 |
146 |
331 |
88 |
1122 |
140 |
222 |
96 |
1346 |
135 |
321 |
89 |
1346 |
119 |
224 |
95 |
1615 |
161 |
372 |
80 |
1615 |
128 |
280 |
93 |
1938 |
153 |
314 |
75 |
1938 |
120 |
245 |
85 |
2326 |
119 |
286 |
69 |
2326 |
103 |
215 |
76 |
2791 |
85 |
207 |
67 |
2791 |
66 |
154 |
75 |
VC |
100 |
100 |
100 |
VC |
100 |
100 |
100 |
LA 1000 µg/mL |
87 |
128 |
99 |
LA 1000 µg/mL |
72 |
77 |
99 |
DNCB 4 µg/mL |
290 |
657 |
59 |
DNCB 4 µg/mL |
236 |
843 |
83 |
3rdexperiment |
|
||||||
Concentration |
RFI CD86 |
RFI CD54 |
Viability |
||||
|
|
||||||
(test substance) [µg/mL] |
mean [%] |
mean [%] |
rel. viability [%] |
||||
779 |
149 |
294 |
98 |
||||
935 |
146 |
326 |
96 |
||||
1122 |
152 |
385 |
93 |
||||
1346 |
141 |
404 |
90 |
||||
1615 |
134 |
414 |
81 |
||||
1938 |
111 |
352 |
75 |
||||
2326 |
93 |
348 |
74 |
||||
2791 |
56 |
219 |
74 |
||||
VC |
100 |
100 |
100 |
||||
LA 1000 µg/mL |
76 |
137 |
99 |
||||
DNCB 4 µg/mL |
251 |
548 |
68 |
Table 4: Historic control data. Data shown of test period Sep 2018 until Feb 2019 (not including present study).
Negative Control (LA 1000 µg/mL) |
CD86 RFI [%] |
CD54 RFI [%] |
viability mean [%] |
rel. viability mean [%] |
||
Min |
61 |
90 |
94 |
99 |
||
Max |
100 |
174 |
98 |
101 |
||
Mean |
82 |
128 |
96 |
100 |
||
SD |
10 |
22 |
1 |
1 |
||
n (experiments) |
|
|
17 |
|
|
Positive Control (DNCB 4 µg/mL) |
CD86 RFI [%] |
CD54 RFI [%] |
viability mean [%] |
rel. viability mean[%] |
||
Min |
184 |
194 |
55 |
57 |
||
Max |
356 |
1095 |
88 |
91 |
||
Mean |
240 |
472 |
72 |
74 |
||
SD |
35 |
240 |
9 |
9 |
||
n (experiments) |
|
|
17 |
|
|
Vehicle Control (culture medium) |
CD86 RFI [%] |
CD54 RFI [%] |
viability mean [%] |
|
||
Min |
79 |
71 |
95 |
|
||
Max |
121 |
129 |
98 |
|||
Mean |
100 |
100 |
96 |
|||
SD |
12 |
12 |
1 |
|||
n (experiments) |
|
|
17 |
|
|
Vehicle Control (DMSO) |
CD86 RFI [%] |
CD54 RFI [%] |
viability mean [%] |
rel. viability mean[%] |
||
Min |
75 |
67 |
94 |
99 |
||
Max |
152 |
165 |
98 |
101 |
||
Mean |
115 |
116 |
97 |
100 |
||
SD |
16 |
21 |
1 |
0 |
||
n (experiments) |
|
|
17 |
|
|
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
The objective was to assess the skin sensitizing potential of the test substance. A combination of the following three in vitro methods, addressing key events of the adverse outcome pathway (AOP) for skin sensitization (OECD, 2012) as defined by the OECD, were part of this in vitro Skin Sensitization Turnkey Testing Strategy:
• protein reactivity (DPRA),
• activation of keratinocytes (LuSens), and
• activation of dendritic cells (h-CLAT).
DPRA:
The reactivity of the test substance towards synthetic cysteine (C)- or lysine (K)-containing peptides was evaluated in the Direct Peptide Reactivity Assay (DPRA). For this purpose, the test substance was incubated with synthetic peptides for ca. 24 hours at ca. 25°C and the remaining non-depleted peptide concentrations were determined by high performance liquid chromatography (HPLC) with gradient elution and UV-detection at 220 nm. The test substance was dissolved at 100 mM in acetonitrile. Three samples of the test substance were incubated with each peptide in ratios of 1:10 (for C-containing peptide) or 1:50
(for K-containing peptide). Additionally, triplicates of the concurrent vehicle control (= VC) were incubated with the peptides. Further, in order to detect possible interference of the test substance with the peptides, a coelution control was performed and the samples were analyzed by measuring UV absorbance at 258 nm in order to calculate the area ratio 220 nm / 258 nm. The following results were obtained in the DPRA:
The test substance was dissolved in acetonitrile at a concentration of 100 mM (colloid solution). The samples of the test substance with the peptides were solutions at the time of preparation. Visual observation after the 24-hour incubation time did not reveal precipitates in any samples of the test substance with the peptides. No co-elution of test substance and peptides was present. The mean C-peptide depletion, caused by the test substance was determined to be 1.32%. The mean K-peptide depletion, caused by the test substance was determined to be -0.21%. Negative depletions were considered to be “zero” for calculation of the mean peptide depletion, which was thus calculated to be 0.66%. Based on the observed results and applying the cysteine 1:10 / lysine 1:50 prediction model cited in chapter 3.10 it was concluded that the test substance shows minimal or no chemical reactivity in the DPRA under the test conditions chosen.
LuSens:
The keratinocyte activating potential of the test substance was evaluated in the LuSens assay. For this purpose, the test substance was incubated with a luciferase reporter cell line (LuSens cells) for ca. 48 hours at 37°C and antioxidant response element (ARE) dependent luciferase activity was measured in a luminometer. In order to determine the concentrations suitable for the main experiment a pre-test (non-GLP)
was performed. Cells were exposed to several concentrations of the test substance and cytotoxicity was determined by MTT assay. The CV75 value (= estimated concentration that affords 75% cell viability) was determined by linear regression from the concentration-response curve to be 1044 μM (corresponding to test substance as provided by the sponsor). In the main test luciferase activity was measured after 48-hour exposure. In parallel a MTT assay was performed to assess cytotoxicity of the test substance. A total of 3 valid experiments were performed. The following results were observed: The test substance was soluble in 4% DMSO in culture medium 3 (4 x stock preparations) and in 1% DMSO in culture medium 3 (final concentrations). No precipitates were noticed in any concentration after 48 hours.
Calculation of an EC1.50 (the concentration resulting in a 1.50-fold luciferase induction) was not applicable as luciferase fold induction did not exceed 1.50. In summary, after 48 hours of exposure to the test substance luciferase activity in LuSens cells was not induced in at least two consecutive concentrations with statistical significance affording at least 70% viability in at least two independent experiments. From this it has to be concluded that the test substance does not have a keratinocyte activating potential.
h-CLAT:
The potential of the test substance to induce the cell membrane markers CD86 and CD54 expression was evaluated in the Human Cell Line Activation Test (h-CLAT). For this purpose, the test substance was incubated with human monocytic leukemia cell line THP-1 for ca. 24 hours at 37°C and membrane marker expression (CD86 / CD54) was measured by flow cytometry.
In order to determine the concentrations suitable for the main experiment a pre-test (non-GLP) was performed. Cells were exposed to several concentrations of the test substance and cytotoxicity was determined thereafter by propidium iodide (PI) intercalation into the DNA. The CV75 value (= estimated concentration that affords 75% cell viability) was determined by linear regression from the concentration-response curve to be 2325 μg/mL (corresponding to test substance as provided by the sponsor).
In the main test after 24-hour exposure THP-1 cells were stained with FITC labeled anti-human-CD86/ anti-human-CD54 antibody and propidium iodide and the fluorescence intensity was analyzed using flow cytometry. A total of 3 valid experiments were performed although the result of the 2nd experiment confirmed the result of the 1st experiment, as one sample instead of two samples was available in the 2nd experiment, only, due to a technical error. The following results were observed:
The test substance was soluble in culture medium (2 x stock preparations and final concentrations). No precipitates were noticed in any concentration after 24 hours.
The EC150% (the concentration resulting in a RFI of 150%) for CD86 was calculated to be 1055 μg/mL (experiment 3). The EC200% (the concentration resulting in a RFI of 200%) for CD54 was calculated to be 1024 μg/mL (experiment 2).
Calculation of EC150% for CD86 and EC200% for CD54 was not applicable for the other experiments.
In summary, after 24 hours of exposure to the test substance, CD86 and CD54 expression was induced in THP-1 cells affording at least 50% viability in at least two independent experiments. From this it has to be concluded that the test substance induces dendritic cell activation.
Table 1: Summary of individual test results.
Test Method
Test Result
Test Evaluation
Direct Peptide Reactivity Assay (DPRA)
1.32% mean peptide depletion (-0.21%
cysteine-peptide depletion; 0.66% lysine- peptide depletion).a
Negative
Keratinocyte Activation Assay - LuSens
In at least two independent experiments
no biologically relevant ARE-dependent
luciferase activity induction was observed.
Negative
Dendritic Cell Line Activation Assay Human Cell Line Activation Test (h-CLAT)
In at least two independent experiments
an induction of the expression of CD86
(above 150%) and CD54 (above 200%)
were observed at sufficiently non-cytotoxic
(cell viability ≥ 50%) concentration.
Positive
a Negative depletions were considered to be “zero” for calculation of mean peptide depletion.
Based on the results summarized in Table 1, the test substance is not peptide reactive, does not activate keratinocytes and activates dendritic cells.
Applying the evaluation criteria ("2 out of 3"), the test substance is predicted not to be a skin sensitizer.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. Negative responses were observed in a direct peptide binding assay (OECD442C) and in an activation of keratinocytes (LuSens) assay (OECD442D). Positive response was observed in an activation of dendritic cells (h-CLAT) assay (OECD442E). The test substance is therefore predicted not to be a skin sensitizer (Evaluation criteria "2 out of 3").
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.